Big Flats, NY – (February 17, 2014) – X-GEN Pharmaceuticals announced today FDA approval to begin marketing and distributing Clonidine Hydrochloride Injection as part of a development and licensing agreement with Exela Pharma Sciences. Exela Pharma Sciences developed and is the commercial manufacturer of the drug product. Clonidine is AP rated to Duraclon® and is used in combination with opiates for the treatment of severe pain in cancer patients that is not adequately relieved by opioid analgesics alone and is more likely to be effective in patients with neuropathic pain than somatic or visceral pain.
The addition of Clonidine to the product portfolio exemplifies X-GEN’s continued emphasis on new product introductions and business alliances serving wide ranging medical needs. Rob Liles, Corporate Vice President, stated that the “overall market for Clonidine is small in the U.S., but we felt it was an important product line expansion for X-GEN given the population it serves. We look for opportunities where X-GEN can improve patient’s quality of life by ensuring that high-quality, low cost treatments are available to the people who need it most.
X-GEN Pharmaceuticals, Inc. is focused on the development, manufacture and delivery of specialty pharmaceutical products which serve the healthcare community as effective, generic treatment choices. X-GEN’s expanding product line offers a broad range of dosage forms including injectables, anti-infective solutions, oral solids, powders for prescription compounding and inhalants. For further information about X-GEN Pharmaceuticals call (866) 390-4411, or visit the web-site at www.x-gen.us.
About Exela Pharma Sciences
Exela develops and manufactures both innovative and generic injectable, ophthalmic, and inhalation pharmaceutical products. Exela, located in Lenoir, NC, operates a sterile manufacturing facility and is committed to providing safe, pure, and effective pharmaceutical products while assuring compliance with cGMP and other FDA regulations.
For further information contact:
X-GEN Pharmaceuticals, Inc.